The role of sildenafil citrate in the protection of gastric mucosa from nonsteroidal anti-inflammatory drug-induced damage.
BACKGROUND
To investigate the protective effects of sildenafil citrate (SC) on indomethacin-induced gastric ulcer in a rat model.


METHODS
Gastric ulcers were induced by oral ingestion of indomethacin. Thirty rats were used in the study. The rats were divided into 3 groups, and given either SC (n=10) at a dose of 50 mg/kg or omeprazole (n=10), or no treatment (n=10, the control group). In addition to the measurements of ulceration areas, the sum of gastric tissue nitrite (NO2-) and nitrate (NO3-) were evaluated as an indicator of gastric tissue NO level. All the measurements were done at 6th hour of oral administration of indomethacin.


RESULTS
The mean values of ulceration areas were 4.0+/-2.31, 3.0+/-2.00, and 21.4+/-8.43 in the SC, omeprazole and control groups, respectively. The mean values of ulceration areas in the SC-treated group was lower than that of the control group. The contents of NO were 32.2+/-3.05, 24.8+/-3.23 and 21.0+/-0.82 (micromol/g protein) in gastric tissue in indomethacin, SC, omeprazole and control groups, respectively, The content of NO in the SC-treated groups was significantly higher than control group (p<0.001).


CONCLUSIONS
Sildenafil citrate may have a role in protecting gastric mucosa from the damage caused by indomethacin. This effect may be associated with the increased level of NO in gastric tissue.
Aydinli
Bülent
B
Department of General Surgery, Medicine Faculty of Atatürk University, Erzurum, Turkey. aydinlib@atauni.edu.tr
Yildirgan
Mehmet Ilhan
MI
Oztürk
Gürkan
G
Atamanalap
Sabri Selçuk
SS
Polat
Kamil Yalçin
KY
Başoğlu
Mahmut
M
Gündoğdu
Cemal
C
Süleyman
Halis
H
Kiziltunç
Ahmet
A
Gürsan
Nesrin
N
Oren
Durkaya
D
D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D007213:Indomethacin; D009569:Nitric Oxide / Q000097:blood; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011687:Purines / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068677:Sildenafil Citrate; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy*; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D009853:Omeprazole; D007213:Indomethacin